NCT00137761View on ClinicalTrials.gov

Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

March 31, 2009

Conditions
Metastatic Pancreatic Carcinoma
Interventions
DRUG

ZD 1839

Taken orally once daily

DRUG

Docetaxel

Given intravenously once weekly for 2 out of 3 weeks

Trial Locations (3)

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00137761 - Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer | Biotech Hunter | Biotech Hunter